Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Pharmacological impact of FLT3 mutations on receptor activity and responsiveness to tyrosine kinase inhibitors
Vanessa Marensi, Karen Keeshan, David J. MacEwan
Biochemical Pharmacology (2020) Vol. 183, pp. 114348-114348
Open Access | Times Cited: 17

Showing 17 citing articles:

The importance of Ras in drug resistance in cancer
Fiona Healy, Ian A. Prior, David J. MacEwan
British Journal of Pharmacology (2021) Vol. 179, Iss. 12, pp. 2844-2867
Open Access | Times Cited: 43
FLT3-selective PROTAC: Enhanced safety and increased synergy with Venetoclax in FLT3-ITD mutated acute myeloid leukemia
Yuxin Tan, Lilan Xin, Qian Wang, et al.
Cancer Letters (2024) Vol. 592, pp. 216933-216933
Closed Access | Times Cited: 7
Comprehensive Molecular Profiling of NPM1-Mutated Acute Myeloid Leukemia Using RNAseq Approach
Jessica Petiti, Ymera Pignochino, Aurora Schiavon, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 7, pp. 3631-3631
Open Access | Times Cited: 4
Acute myeloid leukemia with t(8;21) translocation: Molecular pathogenesis, potential therapeutics and future directions
Pei Han Yu, Ze Yan Zhang, Yuan Yuan Kang, et al.
Biochemical Pharmacology (2025) Vol. 233, pp. 116774-116774
Closed Access
Structural Optimization and MD Simulation Study of Benzimidazole Derivatives as Potent Mutant FLT3 Kinase Inhibitors Targeting AML
Nada Alaa El‐Deen, RosaAnna DeFilippis, Amal Kamal Abdel‐Aziz, et al.
Archiv der Pharmazie (2025) Vol. 358, Iss. 5
Closed Access
Feasible and Rapid Screening of IDH1/2 and FLT3-TKD2 Mutations by High-Resolution Melting for Patients with Acute Myeloid Leukemia
Jose Vicente Gil Ortí, Sandra de las Heras, Alberto Miralles, et al.
Diagnostics (2025) Vol. 15, Iss. 10, pp. 1230-1230
Open Access
Inhibitors of class I HDACs and of FLT3 combine synergistically against leukemia cells with mutant FLT3
Vanessa Wachholz, Al‐Hassan M. Mustafa, Yanira Zeyn, et al.
Archives of Toxicology (2021) Vol. 96, Iss. 1, pp. 177-193
Open Access | Times Cited: 19
Red blood cell membrane-coated FLT3 inhibitor nanoparticles to enhance FLT3-ITD acute myeloid leukemia treatment
Jisheng Liu, Junli Chen, Xifeng Zhang, et al.
Chinese Chemical Letters (2024) Vol. 35, Iss. 9, pp. 109779-109779
Closed Access | Times Cited: 1
Identification of inhibitors targeting the FLT3-ITD mutation through 4D-QSAR, in vitro, and in silico
Dongchen Chu, Cuicui Ji, Liang Yu, et al.
European Journal of Medicinal Chemistry (2024) Vol. 282, pp. 117089-117089
Closed Access | Times Cited: 1
Targeting FMS-like tyrosine kinase 3 (FLT3) in acute myeloid leukemia: Novel molecular approaches and therapeutic challenges
Jan Rataj, Lukáš Górecki, Darina Muthná, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 182, pp. 117788-117788
Open Access | Times Cited: 1
Binding Studies and Lead Generation of Pteridin-7(8H)-one Derivatives Targeting FLT3
Suparna Ghosh, Seung Joo Cho
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 14, pp. 7696-7696
Open Access | Times Cited: 5
Oncogenic Kinase Cascades Induce Molecular Mechanisms That Protect Leukemic Cell Models from Lethal Effects of De Novo dNTP Synthesis Inhibition
Miriam Pons, Yanira Zeyn, Stella Zahn, et al.
Cancers (2021) Vol. 13, Iss. 14, pp. 3464-3464
Open Access | Times Cited: 7
RAS: Circuitry and therapeutic targeting
Gagandeep Singh, Neelam Thakur, Umesh Kumar
Cellular Signalling (2022) Vol. 101, pp. 110505-110505
Closed Access | Times Cited: 3
Redox, cysteines, and kinases—A triad sustaining myeloid leukemia
Vanessa Marensi
Advances in cancer research (2024), pp. 1-68
Closed Access
Unravelling the druggability and immunological roles of the SOCS-family proteins
Dylan M. Lynch, Beth Forrester, Thomas Webb, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access
Association of JAK/STAT pathway gene polymorphisms with EGFR-TKIs adverse drug reactions in patients with advanced NSCLC
Yan Wang, Huijie Qi, Tianxiao Wang, et al.
Research Square (Research Square) (2022)
Open Access | Times Cited: 1
FLT3-ITD-Specific PROTAC: Enhanced Safety and Increased Synergy with Venetoclax in Acute Myeloid Leukemia
Yuxin Tan, Lilan Xin, Qian Wang, et al.
Research Square (Research Square) (2023)
Open Access
Pharmacodynamic Polymorphisms
Matías F. Martínez, Leslie C. Cerpa, Nelson Varela, et al.
Springer eBooks (2022), pp. 853-861
Closed Access
Page 1

Scroll to top